메뉴 건너뛰기




Volumn 56, Issue 12, 2001, Pages 931-933

Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?

Author keywords

Lipid lowering drugs; Peripheral neuropathy; Statins

Indexed keywords

ANTILIPEMIC AGENT;

EID: 0034463955     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000248     Document Type: Article
Times cited : (93)

References (7)
  • 1
    • 0028307576 scopus 로고
    • HMG-CoA reductase inhibitor therapy and peripheral neuropathy
    • Jacobs MB (1994) HMG-CoA reductase inhibitor therapy and peripheral neuropathy. Ann Intern Med 120:970
    • (1994) Ann Intern Med , vol.120 , pp. 970
    • Jacobs, M.B.1
  • 2
    • 0028824025 scopus 로고
    • Lovastatin and peripheral neuropathy
    • Ahmad S (1995) Lovastatin and peripheral neuropathy. Am Heart J 130:1321
    • (1995) Am Heart J , vol.130 , pp. 1321
    • Ahmad, S.1
  • 5
    • 0025856399 scopus 로고
    • Validation of information recorded on general practitioner based computerised data resource in the United Kingdom
    • Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 302:766-768
    • (1991) BMJ , vol.302 , pp. 766-768
    • Jick, H.1    Jick, S.S.2    Derby, L.E.3
  • 6
    • 0034105979 scopus 로고    scopus 로고
    • The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK
    • MacDonald BK, Cockerell OC, Sander WAS, Shorvon SD (2000) The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 123:665-676
    • (2000) Brain , vol.123 , pp. 665-676
    • MacDonald, B.K.1    Cockerell, O.C.2    Sander, W.A.S.3    Shorvon, S.D.4
  • 7
    • 0034685273 scopus 로고    scopus 로고
    • Expressing the magnitude of adverse effects in case-control studies: "the number of patients needed to be treated for one additional patient to be harmed"
    • Bjerre LM, LeLorier J (2000) Expressing the magnitude of adverse effects in case-control studies: "the number of patients needed to be treated for one additional patient to be harmed". BMJ 320:503-506
    • (2000) BMJ , vol.320 , pp. 503-506
    • Bjerre, L.M.1    LeLorier, J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.